AZTR Stock — Azitra Inc: Cash, EV, Pipeline

What they do

We have not commenced commercial operations. Unless otherwise indicated, the terms “Azitra,” Company,” “we,” “us,” and “our” refer to Azitra, Inc. and its wholly-owned subsidiaries. Overview We are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.73

Market cap

$4.4M

Cash

$6.7M

Enterprise value

-$2.3M

Balance sheet

Cash	$6.7M
Debt	$0.0M
Net cash	$6.7M
Enterprise value	-$2.3M
Basic shares	60.6M shares
Fully diluted shares	280.7M shares
Fully diluted market cap	$204.9M
Cash per share	$0.11
Quarterly burn	$3.3M
Cash runway	2.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

60.6M

Pre-funded warrants

42.4M

Options

0.7M

RSUs

0.0M

Warrants

177.1M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

280.7M

Cap table as of 2026-08-11.

Price history

Loading AZTR daily closes…

Loading price history…

Next catalyst

ATR-04 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	ATR-04 first cohort of Phase 1/2 in EGFR inhibitor-associated rash · NCT06830863	Phase 1/2	EGFR inhibitor-associated rash	Q4 2026
Feb 26 - Apr 9 in 16 wks	ATR04-484	Phase 2	EGFR Inhibitor-associated Rash	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ATR-12

Phase 1 · Active Modality: live biotherapeutic (engineered S. epidermidis, topical)

Aliases SE351, ATR-12-351

Target LEKTI (lympho-epithelial Kazal-type related inhibitor); replaces deficient LEKTI to counter dysregulated skin serine protease activity

Partnerships Fred Hutchinson Cancer Center: exclusive worldwide royalty-bearing license to SyMPL minicircle plasmid technology for genetic engineering (filing notes current candidates were engineered without SyMPL)

Indications

Netherton syndrome (Phase 1)

Status note Phase 1b first patient dosed August 2024; initial safety results reported H1 2025. In June 2026 the Company announced it paused enrollment for capital preservation; filing states it may resume development and has developed improved topical formulations and next-generation candidates.

ATR-04

Phase 1 · Active Modality: live biotherapeutic (engineered S. epidermidis, topical)

Aliases SE484, ATR-04-484

Target IL-36γ (Interleukin-36 gamma) inhibition

Partnerships Fred Hutchinson Cancer Center: exclusive worldwide royalty-bearing license to SyMPL minicircle plasmid technology for genetic engineering (filing notes current candidates were engineered without SyMPL)

Indications

EGFR inhibitor-associated papulopustular rash in cancer patients (Phase 1)

Catalysts

— around Q4 2026

Status note FDA IND clearance August 2024; Fast Track designation September 2024; first patient dosed in Phase 1/2 trial in Q3 2025. Engineered strain SE484 is D-alanine auxotrophic.

ATR-01

Preclinical · Active Modality: live biotherapeutic

Indications

not disclosed (Preclinical)

Status note Named as one of three lead product candidates; IND-enabling studies ongoing in 2026 per this filing. No indication or target stated.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ATR04-484
Lead indication	EGFR Inhibitor-associated Rash
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06830863	Phase 2	Recruiting	Sponsor	AZTR	—	EGFR Inhibitor-associated Rash	Q4 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Azitra Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	5,285,476	+5,285,476	0.68%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AZTR — Azitra Inc ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

AZTR — Azitra Inc